

Study Number: C15002-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

C Number:

Study Gender:

PWG Approval Date

PA41: Clinical Chemistry Summary

Test Compound: 1,2-bis(pentabromophenyl)ethane

CAS Number: 84852-53-9

C15002-01

Male

See web page for date of PWG Approval

Date Report Requested: 04/08/2019

Time Report Requested: 11:02:32

Lab: Battelle

Study Number: C15002-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-bis(pentabromophenyl)ethane

CAS Number: 84852-53-9

Date Report Requested: 04/08/2019

Time Report Requested: 11:02:32

Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups (mg/kg)				
		0	0.1	0.97	9.71	97.1
Urea Nitrogen (mg/dL)	SD 5	11.7 ± 0.9 (6)	12.0 ± 0.5 (6)	14.0 ± 0.7 (6)	13.2 ± 0.8 (6)	12.7 ± 1.0 (6)
Percent of Control			102.9	120.0	112.9	108.6
Creatinine (mg/dL)	SD 5	0.37 ± 0.02 (6)	0.37 ± 0.02 (6)	0.38 ± 0.02 (6)	0.40 ± 0.00 (6)	0.40 ± 0.00 (6)
Percent of Control			100.00	104.55	109.09	109.09
Glucose (mg/dL)	SD 5	239.8 ± 20.2 (6)	241.2 ± 7.3 (6)	259.2 ± 14.4 (6)	240.2 ± 11.6 (6)	265.5 ± 7.7 (6)
Percent of Control			100.6	108.1	100.1	110.7
Sodium (mmol/L)	SD 5	147.3 ± 0.4 (6)	148.5 ± 0.4 (6)	147.5 ± 0.4 (6)	147.7 ± 0.5 (6)	148.2 ± 0.4 (6)
Percent of Control			100.8	100.1	100.2	100.6
Potassium (mmol/L)	SD 5	7.3 ± 0.4 (6)	7.0 ± 0.2 (6)	7.6 ± 0.3 (6)	7.1 ± 0.2 (6)	7.7 ± 0.1 (6)
Percent of Control			95.9	104.1	97.7	105.3
Chloride (mmol/L)	SD 5	102.3 ± 0.6 (6)	103.0 ± 0.4 (6)	102.3 ± 0.2 (6)	101.7 ± 0.9 (6)	102.2 ± 0.5 (6)
Percent of Control			100.7	100.0	99.3	99.8
Total Protein (g/dL)	SD 5	5.70 ± 0.07 (6) *	5.63 ± 0.12 (6)	5.80 ± 0.09 (6)	5.78 ± 0.21 (6)	5.82 ± 0.06 (6)
Percent of Control			98.83	101.75	101.46	102.05
Globulin (g/dL)	SD 5	1.42 ± 0.03 (6)	1.37 ± 0.05 (6)	1.53 ± 0.07 (6)	1.50 ± 0.15 (6)	1.43 ± 0.06 (6)
Percent of Control			96.47	108.24	105.88	101.18
A/G Ratio	SD 5	3.03 ± 0.06 (6)	3.13 ± 0.06 (6)	2.81 ± 0.11 (6)	2.95 ± 0.21 (6)	3.08 ± 0.13 (6)
Percent of Control			103.41	92.65	97.43	101.78
Albumin (g/dL)	SD 5	4.28 ± 0.05 (6)	4.27 ± 0.08 (6)	4.27 ± 0.04 (6)	4.28 ± 0.09 (6)	4.38 ± 0.02 (6)
Percent of Control			99.61	99.61	100.00	102.33
Cholesterol (mg/dL)	SD 5	139.7 ± 5.5 (6)	132.7 ± 7.6 (6)	134.5 ± 5.9 (6)	143.8 ± 9.9 (6)	137.2 ± 4.6 (6)
Percent of Control			95.0	96.3	103.0	98.2

Study Number: C15002-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-bis(pentabromophenyl)ethane

CAS Number: 84852-53-9

Date Report Requested: 04/08/2019

Time Report Requested: 11:02:32

Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups (mg/kg)				
		0	0.1	0.97	9.71	97.1
Triglyceride (mg/dL)	SD 5	76.0 ± 8.1 (6)	70.0 ± 7.2 (6)	63.8 ± 6.5 (6)	71.3 ± 7.1 (6)	72.7 ± 4.5 (6)
Percent of Control			92.1	84.0	93.9	95.6
Alanine Aminotransferase (IU/L)	SD 5	49.2 ± 2.7 (6)	51.3 ± 2.8 (6)	53.5 ± 2.8 (6)	50.3 ± 1.9 (6)	56.5 ± 4.2 (6)
Percent of Control			104.4	108.8	102.4	114.9
Creatine Kinase (IU/L)	SD 5	195.0 ± 9.1 (6)	191.7 ± 11.8 (6)	195.0 ± 13.0 (6)	172.3 ± 8.9 (6)	196.5 ± 18.0 (6)
Percent of Control			98.3	100.0	88.4	100.8
Sorbitol Dehydrogenase (IU/L)	SD 5	4.1 ± 0.5 (6)	4.3 ± 0.8 (6)	4.8 ± 0.5 (6)	4.9 ± 0.6 (6)	4.0 ± 0.6 (6)
Percent of Control			105.3	115.4	119.0	96.0
Bile salt/acids (umol/L)	SD 5	48.5 ± 5.0 (6)	37.5 ± 4.3 (6)	59.3 ± 10.5 (6)	49.8 ± 6.8 (6)	64.3 ± 8.8 (6)
Percent of Control			77.3	122.3	102.7	132.6

Study Number: C15002-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-bis(pentabromophenyl)ethane

CAS Number: 84852-53-9

Date Report Requested: 04/08/2019

Time Report Requested: 11:02:32

Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups 970
Urea Nitrogen (mg/dL)	SD 5	12.3 ± 0.7 (6)
Percent of Control		105.7
Creatinine (mg/dL)	SD 5	0.38 ± 0.02 (6)
Percent of Control		104.55
Glucose (mg/dL)	SD 5	234.3 ± 10.0 (6)
Percent of Control		97.7
Sodium (mmol/L)	SD 5	148.5 ± 0.3 (6)
Percent of Control		100.8
Potassium (mmol/L)	SD 5	7.6 ± 0.2 (6)
Percent of Control		104.6
Chloride (mmol/L)	SD 5	102.5 ± 0.7 (6)
Percent of Control		100.2
Total Protein (g/dL)	SD 5	6.08 ± 0.21 (6)
Percent of Control		106.73
Globulin (g/dL)	SD 5	1.68 ± 0.14 (6)
Percent of Control		118.82
A/G Ratio	SD 5	2.69 ± 0.19 (6)
Percent of Control		88.86
Albumin (g/dL)	SD 5	4.40 ± 0.07 (6)
Percent of Control		102.72
Cholesterol (mg/dL)	SD 5	152.2 ± 4.4 (6)
Percent of Control		108.9

Study Number: C15002-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 1,2-bis(pentabromophenyl)ethane
CAS Number: 84852-53-9

Date Report Requested: 04/08/2019
Time Report Requested: 11:02:32
Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups
		970
Triglyceride (mg/dL)	SD 5	68.0 ± 7.6 (6)
Percent of Control		89.5
Alanine Aminotransferase (IU/L)	SD 5	59.3 ± 3.7 (6)
Percent of Control		120.7
Creatine Kinase (IU/L)	SD 5	204.0 ± 7.2 (6)
Percent of Control		104.6
Sorbitol Dehydrogenase (IU/L)	SD 5	5.3 ± 0.9 (4)
Percent of Control		128.7
Bile salt/acids (umol/L)	SD 5	45.3 ± 6.8 (6)
Percent of Control		93.5

Study Number: C15002-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 1,2-bis(pentabromophenyl)ethane
CAS Number: 84852-53-9

Date Report Requested: 04/08/2019
Time Report Requested: 11:02:32
Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

Two values for Sorbitol Dehydrogenase in the 970 mg/kg group were excluded.

**** END OF REPORT ****